SCHEDULE: Farallon Capital Amends Assembly Biosciences Stake
Amendment to Schedule 13G
Farallon Capital Management and its affiliates updated their beneficial ownership in Assembly Biosciences, Inc., reporting a collective 7.8% stake and disclosing recent management changes within their own firm.
Summary
- Farallon Capital and its affiliated entities and individuals collectively reported beneficial ownership of 1,227,590 shares of Assembly Biosciences, Inc. common stock.
- This represents a 7.8% stake in the company, as reported by several individual managing members and senior managing members of Farallon's general partners.
- Farallon Capital Partners, L.P. holds 1.5% (239,462 shares), Farallon Capital Institutional Partners, L.P. holds 1.4% (224,245 shares), and Farallon Capital Offshore Investors II, L.P. holds 3.1% (497,192 shares), among other Farallon funds.
- The filing also disclosed ownership of 510,205 Class A Warrants and 510,205 Class B Warrants, totaling 1,020,410 warrants, which are subject to a 4.99% beneficial ownership limitation upon exercise.
- The reporting persons assume the warrants are not exercisable within 60 days of the filing date and therefore do not confer beneficial ownership of any underlying shares for the purpose of this report.
- The filing is an Amendment No. 1 to Schedule 13G, filed under Rule 13d-1(c).
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive signal. While a 13G indicates passive intent, a significant stake from a reputable institutional investor like Farallon Capital can be interpreted as a vote of confidence in Assembly Biosciences' long-term value proposition, especially given the warrant holdings.
Positives
- Significant institutional ownership by Farallon Capital, a prominent investment firm, may signal confidence in Assembly Biosciences' long-term prospects.
- The disclosure of warrant holdings indicates a potential for increased future investment, albeit subject to beneficial ownership limitations.
Risks
- The beneficial ownership limitation on warrants (4.99%) could restrict Farallon's ability to rapidly increase its stake through warrant exercise, potentially limiting its influence or flexibility.
- Changes in the Farallon management team, while internal to Farallon, could theoretically lead to shifts in investment strategy or focus, though no such intent is stated.
Future Outlook
The filing does not provide forward-looking statements or guidance regarding Assembly Biosciences' operational or financial performance. It focuses solely on beneficial ownership disclosure.
Industry Context
StockSavvy.ai notes that a Schedule 13G filing from a significant institutional investor like Farallon Capital typically indicates a passive investment intent, as certified by the filing. While not an endorsement of the company's immediate prospects, a substantial stake from a well-known fund can attract attention from other institutional investors, potentially signaling perceived long-term value in the biotechnology sector, where Assembly Biosciences operates. This type of filing is a standard disclosure for large passive stakes, differentiating it from an activist 13D filing.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Managing Member of Farallon General Partner, Manager of FCIP V General Partner, Manager of F5MI General Partner | NA | Avner A. Husen | 2026-01-01 | Became a member/manager of the respective Farallon entities. |
| Managing Member of Farallon General Partner, Manager of FCIP V General Partner, Manager of F5MI General Partner | Richard B. Fried | NA | 2025-12-31 | Ceased to be a member/manager of the respective Farallon entities. |
| Managing Member of Farallon General Partner, Manager of FCIP V General Partner, Manager of F5MI General Partner | Rajiv A. Patel | NA | 2025-12-31 | Ceased to be a member/manager of the respective Farallon entities. |
| Managing Member of Farallon General Partner, Manager of FCIP V General Partner, Manager of F5MI General Partner | William Seybold | NA | 2025-12-31 | Ceased to be a member/manager of the respective Farallon entities. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Management Structure Change | Avner A. Husen joined as a managing member/manager across key Farallon entities, while Richard B. Fried, Rajiv A. Patel, and William Seybold departed from similar roles. These are internal governance changes within the reporting entity (Farallon Capital) that affect their oversight of the investment in Assembly Biosciences. | 2025-12-31 / 2026-01-01 | These changes reflect internal personnel shifts within Farallon Capital and do not directly impact Assembly Biosciences' corporate governance structure. However, they could subtly influence Farallon's investment strategy or engagement with Assembly Biosciences over time. |
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Farallon Capital may instill confidence among existing shareholders and attract new investors, potentially influencing stock valuation.
- Management: Assembly Biosciences' management should be aware of a large, passive institutional holder, though the 13G filing indicates no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Date of event requiring the filing of this statement, and effective date for cessation of Richard B. Fried, Rajiv A. Patel, and William Seybold as managing members/managers of Farallon entities. |
| 2026-01-01 | Effective date for Avner A. Husen becoming a managing member/manager of Farallon entities. |
| 2026-02-09 | Date of signing and filing of the Schedule 13G Amendment. |
| 2026-11-15 | Date when Class B Warrants become exercisable. |
Recommendation
holdThe filing primarily reports a passive beneficial ownership stake by Farallon Capital and internal management changes within Farallon. While a significant institutional investment can be a positive signal, the 13G explicitly states no intent to influence control, and no new operational or financial information about Assembly Biosciences is provided. Therefore, a 'hold' recommendation is appropriate, acknowledging the institutional interest without suggesting immediate action based solely on this ownership disclosure.
Keywords
Assembly Biosciences, Farallon Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Warrants, Biotechnology, Investment Filing, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.